SAN DIEGO--(BUSINESS WIRE)--Orexigen(TM) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the European Patent Office has issued a Decision to Grant a Patent covering compositions and uses of bupropion and naltrexone for affecting weight loss. These two drugs are the active constituents in Contrave™, Orexigen’s lead product candidate for the treatment of obesity. This development is an important milestone toward an eventual patent validation in individual European countries. This patent, once issued, would provide exclusive rights on this combination in those countries until 2024.
